

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: )  
TAKAO NAKAJIMA, ET AL. ) : Examiner: Laura Lynne Stockton  
Application No.: 10/584,633 ) : Group Art Unit: 1626  
Filed: June 26, 2006 ) : Confirmation No. 5585  
U.S. Patent No. 7,718,808 )  
Issue Date: May 18, 2010 )  
For: THIAZOLE DERIVATIVES : November 9, 2011

Attention: Mary Diggs, Supervisor  
Decisions & Certificates of Correction Branch  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

REQUEST FOR RECONSIDERATION

Sir:

This is in response to the U.S. Patent and Trademark Office Communication re Request for Certificate of Correction dated August 24, 2011 in the above-identified patent.

The Communication denied correction of the specific errors noted therein. This decision is not at all well-understood, nor is in conformity with Title 35, the USPTO Rules of Practice or MPEP §1400, as discussed below in detail.

That is, as to the changes themselves, *each* simply concerns a mere punctuation or spelling error, as noted below.

<u>Correction</u>	<u>Comment</u>
<b>COLUMN 192</b> Line 50, "of" should be deleted	Delete "of"
<b>COLUMN 198</b> Line 61, "Compound 115" should read --Compound 116--	Change "115" to --116--
<b>COLUMN 199</b> Line 48, " $^1\text{H}$ NMR (CDCl <sub>3</sub> , ppm):" should read -- $^1\text{H}$ NMR (CDCl <sub>3</sub> , $\delta$ ppm):--	Add " $\delta$ "
<b>COLUMN 216</b> Line 7, "Compound 166" should read --Compound 171--	Change "166" to --171--
<b>COLUMN 218</b> Line 41, "(155'mg," should read --155 mg--	Delete "' "
<b>COLUMN 226</b> Line 11, "(31.1 mg," should read --(311 mg,--	Change "31.1" to --311--
<b>COLUMN 244</b> Line 10, "6.65 (dd, j=1.6, 3.5Hz,—1H)," should read --6.65 (dd, J=1.6, 3.5Hz, 1H),--	Change "—" to --,--
<b>COLUMN 269</b> Line 61, "crude." should read --crude--	Delete "."
<b>COLUMN 273</b> Line 51, "8.75 (br s, 2H)" should read --8.75 (br s, 2H).--	Add --.--
<b>COLUMN 287</b> Line 9, "N-[5-(Cyclopentylcarbonyl)-4-(2-furyl)thiazol-2-]" should read --N-[5-(Cyclopentylcarbonyl)-4-(2-furyl)thiazol-2- --	Change "Cyclopentylcarbonyl" to --Cyclopentylcarbonyl--
<b>COLUMN 290</b> Line 19, "Compound" (first occurrence) should read --Compound 443--	Add --443--

<u>Correction</u>	<u>Comment</u>
<b><u>COLUMN 300</u></b> Line 59, "(111 mg, 53" should read --111 mg, 53%)--	Add --%--
<b><u>COLUMN 324</u></b> Line 63, "J=11.9," should read --J=1.9,--	Change "11.9" to --1.9--
<b><u>COLUMN 325</u></b> Line 10, "(122 mg;" should read --(122 mg,--	Change ";" to --,--
<b><u>COLUMN 327</u></b> Line 38, "7.7%). "should read --77%).--	Change "7.7" to --77--
<b><u>COLUMN 329</u></b> Line 7, "2-methoxy-2-methylpropylpiperazine" should read --1-(2-methoxy-2-methylpropyl)piperazine--	Change "methylpropylpiperazine" to --methylpropyl)piperazine--
<b><u>COLUMN 330</u></b> Line 7, "added" should read --was added--	Add --was--
<b><u>COLUMN 332</u></b> Line 15, "9.00 mmol)" should read --0.900 mmol)--; Line 36, "9.00 mmol)" should read --0.900 mmol)--; and Line 56, "9.00 mmol)" should read --0.900 mmol)--	Change "9.00" to --0.900-- Change "9.00" to --0.900-- Change "9.00" to --0.900--
<b><u>COLUMN 333</u></b> Line 8, "9.00 mmol)" should read --0.900 mmol)--; and Line 26, "9.00 mmol)" should read --0.900 mmol)--	Change "9.00" to --0.900--; Change "9.00" to --0.900--
<b><u>COLUMN 351</u></b> Line 4, "sulfate;" should read --sulfate,--	Change ";" to --,--
<b><u>COLUMN 352</u></b> Line 43, "8.dd" should read --8.33--	Change "dd" to --33--

As discussed above, since none of these changes is understood to be anything other than "a mistake of a clerical or typographical nature, or of minor character", each is in conformity with the Rules of Practice and is accordingly entitled to correction under 35 U.S.C. §255.

Therefore, if for any reason any of the foregoing corrections is again denied, the USPTO is respectfully requested to report its reasons for such denial in detail.

Entry hereof and correction of the above-identified patents as previously requested are earnestly solicited.

Patentees' undersigned attorney may be reached in our New York office by telephone at (212) 218-2100. All correspondence should continue to be directed to our address given below.

Respectfully submitted,

/Lawrence S. Perry/  
Lawrence S. Perry  
Attorney for Patentees  
Registration No. 31,865

FITZPATRICK, CELLA, HARPER & SCINTO  
1290 Avenue of the Americas  
New York, New York 10104-3800  
Facsimile: (212) 218-2200

LSP/ac